All In Biotech

NDA 204399 · Upsher Smith Labs

Vogelxo

Testosterone · Transdermal · Androgen

Last checked: Nov 20, 2026Latest source record: Jul 11, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Jun 4, 2014

Approved uses

1

Original approval plus efficacy supplements

Registered trials

728

173 Phase 3, 64 recruiting

FAERS reports

19,084

10,933 serious, 780 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SECONDARY EXPOSURE TO TESTOSTERONE Virilization has been reported in children who were secondarily exposed to testosterone gel [see Warnings and Precautions (5.2) and Adverse Reactions (6.2) ] . Children should avoid contact with unwashed or unclothed application sites in men using testosterone gel [see Dosage and Administration (2.2) and Warnings and Precautions (5.2) ] . Healthcare providers should advise patients to strictly adhere to recommended instructions for use [see Dosage and Administration (2.2) , Warnings and Precautions (5.2) and Patient Counseling Information (17) ] . WARNING: SECONDARY EXPOSURE TO TESTOSTERONE See full prescribing information for complete boxed warning Virilization has been reported in children who were secondarily exposed to testosterone gel. ( 5.2 , 6.2 ) Children should avoid contact with unwashed or unclothed application sites in men using...

What it is approved for

From the label in effect Jul 14, 2025.

Vogelxo is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Vogelxo is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired). ( 1 ) Hypogonadotropic hypogonadism (congenital or acquired). ( 1 ) Limitations of Use: Safety and efficacy of Vogelxo in men with age-related hypogonadism have not been established ( 1 ) Safety and efficacy of Vogelxo in males less than 18 years old have not been established ( 8.4 ) Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure ( 1 , 12.3 ) Limitations of Use: Safety and efficacy of Vogelxo in men with "age-related hypogonadism" (also referred to as "late-onset hypogonadism") have not been established. Safety and efficacy of Vogelxo in males less than 18 years old have not been established [see Use in Specific Populations (8.4) ] . Topical...

Mechanism: Endogenous androgens, including testosterone and dihydrotestosterone (DHT) are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. These effects include the growth and maturation of the prostate, seminal vesicles, penis, and scrotum; the development of male hair distribution, such as facial, pubic, chest, and axillary hair; laryngeal enlargement, vocal cord thickening, and alterations in body musculature and fat distribution. Male hypogonadism, a clinical syndrome resulting from insufficient secretion of testosterone,...

Therapeutic areas: Endocrinology and women's health

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • VOGELXO · TESTOSTERONE 12.5MG/1.25GM ACTUATION · GEL, METERED, TRANSDERMAL · Prescription · TE BX
  • VOGELXO · TESTOSTERONE 50MG/5GM PACKET · GEL, TRANSDERMAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Testosterone" as an intervention, any sponsor and status, largest first.

All 728 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective1,467
  • off label use1,232
  • fatigue1,182
  • nausea858
  • pain778
  • headache776
  • diarrhoea628
  • anxiety612
  • asthenia598
  • arthralgia595
  • dizziness593
  • dyspnoea549

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004169
2005126
2006139
2007156
2008188
2009248
2010307
2011334
2012875
2013367
2014556
20151,104
20161,061
2017978
20181,138
20191,227
20201,198
20211,206
20221,419
20231,550
20241,641
20251,722
20261,375

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 6,506 on PubMed

Sponsor: Upsher Smith Labs

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.